查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153459

全球切片檢查市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Cancer Biopsy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 203 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球癌症切片檢查市場預計將從2025年的372.7億美元成長至2034年的804.8億美元，並預計在2026年至2034年間以8.93%的複合年成長率成長。全球癌症切片檢查市場正經歷顯著成長，這主要歸因於癌症發病率的上升以及早期診斷重要性的日益凸顯。切片檢查是確診癌症和製定合適治療方案的關鍵步驟。隨著人們對癌症篩檢意識的提高以及微創診斷方法的普及，醫療專業人員越來越依賴先進的切片檢查技術來提高診斷準確性和改善患者預後。

推動該市場成長的因素包括診斷影像技術的進步、液態生物檢體技術的發展以及癌症研究投入的增加。液態生物檢體尤其引人注目，因為它可以透過血液樣本檢測癌症生物標記物，從而減少侵入性手術的需求。此外，隨著精準醫療和個人化癌症治療方法的日益普及，對可靠切片檢查診斷的需求也不斷成長。

隨著技術創新不斷革新癌症診斷，癌症切片檢查市場前景看好。新的診斷技術、人工智慧在病理學中的應用以及生物標記檢測方法的改進，有望提升診斷能力。在醫療成本不斷上漲和政府大力推動癌症早期篩檢計畫的推動下，預計未來幾年該市場將迎來顯著成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球癌症切片檢查市場：依產品分類

  • 市場分析、洞察與預測
  • 平台和設備
  • 試劑盒和試劑
  • 服務

第5章 全球癌症切片檢查市場：按類型分類

  • 市場分析、洞察與預測
  • 組織切片檢查
  • 液態生物檢體
  • 其他

第6章：全球癌症切片檢查市場：按應用領域分類

  • 市場分析、洞察與預測
  • 乳癌
  • 結腸癌
  • 子宮頸癌
  • 肺癌
  • 攝護腺癌
  • 皮膚癌
  • 血癌
  • 腎癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他

第7章 全球癌症切片檢查市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • QIAGEN NV
    • IlluminaInc
    • ANGLE Plc
    • Becton, Dickinson And Company
    • Myriad GeneticsInc
    • HologicInc
    • Thermo Fisher Scientific Inc
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Lucence Health Inc
    • GRAILInc
    • Guardant HealthInc
    • Exact Sciences Corporation
    • Freenome HoldingsInc
    • BiodesixInc
    • Oncimmune Holdings Plc
    • Epigenomics AG
    • NateraInc
    • PersonalisInc
    • HelioHealth
簡介目錄
Product Code: VMR11213945

The global cancer biopsy market size is expected to reach USD 80.48 Billion in 2034 from USD 37.27 Billion in 2025, growing at a CAGR of 8.93% during 2026-2034.The global cancer biopsy market is witnessing substantial growth due to the increasing prevalence of cancer and the rising importance of early disease diagnosis. Biopsy procedures are essential for confirming cancer diagnoses and determining appropriate treatment strategies. With growing awareness about cancer screening and the rising adoption of minimally invasive diagnostic procedures, healthcare providers are increasingly relying on advanced biopsy techniques to improve diagnostic accuracy and patient outcomes.

Several factors are driving the growth of this market, including advancements in imaging technologies, the development of liquid biopsy techniques, and increasing investments in oncology research. Liquid biopsy, in particular, has gained attention as it allows the detection of cancer biomarkers through blood samples, reducing the need for invasive procedures. Additionally, the growing adoption of precision medicine and personalized cancer treatment approaches is increasing the demand for reliable biopsy diagnostics.

The future of the cancer biopsy market looks promising as technological innovations continue to transform cancer diagnostics. Emerging diagnostic technologies, integration of artificial intelligence in pathology, and improved biomarker detection methods are expected to enhance diagnostic capabilities. With increasing healthcare expenditure and government initiatives promoting early cancer detection programs, the market is expected to experience significant growth in the coming years.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

  • Platforms & Instruments
  • Kits & Reagents
  • Services

By Type

  • Tissue Biopsies
  • Liquid Biopsies
  • Others

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

COMPANIES PROFILED

  • QIAGEN N.V., Illumina, Inc., ANGLE plc, Becton, Dickinson and Company, Myriad Genetics, Inc., Hologic, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Health Inc., GRAIL, Inc., Guardant Health, Inc., Exact Sciences Corporation, Freenome Holdings, Inc., Biodesix, Inc., Oncimmune Holdings plc, Epigenomics AG, Natera, Inc., Personalis, Inc., HelioHealth

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Platforms & Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOPSY MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Tissue Biopsies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Liquid Biopsies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOPSY MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.8. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.9. Kidney Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.10. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.11. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.12. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.13. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOPSY MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Product
    • 7.2.2 By Type
    • 7.2.3 By Application
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Product
    • 7.3.2 By Type
    • 7.3.3 By Application
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Product
    • 7.4.2 By Type
    • 7.4.3 By Application
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Product
    • 7.5.2 By Type
    • 7.5.3 By Application
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Product
    • 7.6.2 By Type
    • 7.6.3 By Application
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER BIOPSY INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 QIAGEN N.V
    • 9.2.2 IlluminaInc
    • 9.2.3 ANGLE Plc
    • 9.2.4 Becton, Dickinson And Company
    • 9.2.5 Myriad GeneticsInc
    • 9.2.6 HologicInc
    • 9.2.7 Thermo Fisher Scientific Inc
    • 9.2.8 Danaher Corporation
    • 9.2.9 F. Hoffmann-La Roche Ltd
    • 9.2.10 Lucence Health Inc
    • 9.2.11 GRAILInc
    • 9.2.12 Guardant HealthInc
    • 9.2.13 Exact Sciences Corporation
    • 9.2.14 Freenome HoldingsInc
    • 9.2.15 BiodesixInc
    • 9.2.16 Oncimmune Holdings Plc
    • 9.2.17 Epigenomics AG
    • 9.2.18 NateraInc
    • 9.2.19 PersonalisInc
    • 9.2.20 HelioHealth